Netherlands-based Qiagen NV has acquired Corbett Life Science, a privately-held developer, manufacturer and distributor of life sciences instrumentation headquartered in Sydney, Australia. The transaction is valued at around $66.0 million in cash (subject to certain customary purchase price adjustments), $4.0 million in restricted Qiagen common stock and performance and development milestone payments and other contingencies of up to about $65.0 million over the next four years, for a total of up to $135.0 million.
Corbett is best known for having developed the world's first rotary real-time polymerase chain reaction cycler system - the Rotor-Gene - which make specific sequences of DNA and RNA targets visible through amplification and quantifiable through real-time measurement of such amplification. The addition of this proprietary PCR detection technology extends Qiagen's molecular testing solution portfolio and enhances the company's options to offer sample and assay technology solutions spanning from sample to result, the Dutch firm notes, and add around $40.0 million to full-year 2009 revenues.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze